Stock FGEN FIBROGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News FibroGen, Inc.

Equities

FGEN

US31572Q8087

Real-time Estimate Cboe BZX
Other stock markets
 03:05:11 2024-06-03 pm EDT 		5-day change 1st Jan Change
1.235 USD +2.92% Intraday chart for FibroGen, Inc. -3.12% +39.91%
May. 23 FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting CI
May. 07 Top Premarket Gainers MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
AQ
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting
CI
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
AQ
FibroGen : Corporate Presentation – May 2024
PU
Top Premarket Gainers
MT
FibroGen to Participate in Upcoming Investor Conferences
AQ
Transcript : FibroGen, Inc., Q1 2024 Earnings Call, May 06, 2024
FibroGen: Q1 Earnings Snapshot
AQ
Earnings Flash (FGEN) FIBROGEN Posts Q1 Revenue $55.9M, vs. Street Est of $36.4M
MT
FibroGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
FibroGen Reports First Quarter 2024 Financial Results
AQ
FibroGen to Report First Quarter 2024 Financial Results
AQ
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting
CI
Faron Pharmaceuticals reappoints former finance chief on interim basis
AN
Top Midday Decliners
MT
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise
MT
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
AQ
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FGEN Stock
  4. News FibroGen, Inc.